Semaglutide for HIV-Associated Lipohypertrophy
Trial Summary
What is the purpose of this trial?
This trial tests semaglutide, a medication that controls blood sugar, in people with HIV who have abnormal fat accumulation. It aims to see if the drug can reduce fat, improve blood vessel function, and lower inflammation. Semaglutide has been used to improve blood sugar levels and reduce body weight in individuals with obesity and type 2 diabetes.
Research Team
Grace McComsey, MD
Principal Investigator
Case Western Reserve University
Allison R Eckard, MD
Principal Investigator
Medical University of South Carolina
Eligibility Criteria
Adults over 18 with HIV and obesity (BMI ≥25 kg/m²) who have experienced increased abdominal size after starting HIV treatment. Participants must be on stable antiretroviral therapy, with controlled HIV-1 RNA levels for at least 6 months, and not planning to change their HIV medication or start a weight loss program during the study. Women of childbearing potential must test negative for pregnancy and agree to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive semaglutide or placebo for 32 weeks, including an 8-week dose escalation phase followed by 24 weeks at full dose
Follow-up
Participants are monitored for sustainability of treatment effects after discontinuation
Treatment Details
Interventions
- Semaglutide Injectable Product
Find a Clinic Near You
Who Is Running the Clinical Trial?
Case Western Reserve University
Lead Sponsor
Medical University of South Carolina
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator